Boehringer opens the doors to new Austrian biopharma production site
The LSCC provides an additional 30% in mammalian large-scale capacity for the company's own pipeline and for third parties
After investing more than €700 million in a new biopharma production site in Vienna, Austria, Boehringer Ingelheim has officially announced the facility open for business.
Boehringer will use the facility, which goes by the name of Large Scale Cell Culture (LSCC) and represents the single largest investment in the company's history, to produce biopharmaceuticals for its own pipeline as well as for customer projects.
According to the company, the LSCC's incorporated smart technologies and artificial intelligence applications provides a high degree of digitalisation and automation, making it "one of the most advanced of its kind".
With a total volume of 185,000 L, the facility's fermenters provide an additional 30% in mammalian large-scale capacity. Furthermore, the plant's short product changeover times or simultaneous production of different products enables it to supply a variety of molecule formats, such as monoclonal antibodies, enzymes, cytokines and other recombinant proteins.
Hubertus von Baumbach, Chairman of the Board of Managing Directors, said Boehringer's investment in additional state-of-the-art production platforms reflects the fast growth of innovative biopharmaceutical treatments. He added that the company wants to put "every effort" into advancing the science that will enable it to achieve "the next medical breakthrough".
Related News
-
News Forge Biologics to provide CDMO support for Solid Biosciences' preclinical gene therapy
By providing AAV process development, scale up and cGMP manufacturing services, Forge hopes to bolster Solid's gene therapy pipeline -
News Thermo Fisher takes on operational responsibility for new Swiss biologics manufacturing site
The 1.5 million-sq. ft Switzerland-based facility is part of the company's strategic partnership with CSL Limited -
News Advanced Computing in Pharma: 3 reasons why quantum computing could disrupt R&D
Quantum computing technology uses quantum systems called “qubits”. They work with non-binary values, unlike classical computing which uses only bits with values of 0 or 1, and can overlap each other and act as a group. The result is a ... -
News Fujifilm begins commissioning phase of new Netherlands-based manufacturing facility
The facility will increase the production capacity of cell culture media products and provide a hub for European and global markets -
News New Thermo system makes AAV production more efficient and scalable
The company's new Gibco AAV-MAX Helper Free AAV Production System helps reduce production costs and streamline transition from research to clinical environments -
News Clean Cells to invest €13 million to create Europe's largest cell bank production site
The expansion is anticipated to speed up development and time-to-market of novel treatments and vaccines for COVID‑19 -
News AGC Biologics to increase capacity for pDNA and mRNA manufacturing in Heidelberg
The expansion plans include an additional manufacturing line, a new cleanroom and a new process development lab -
News Thermo Fisher to build facility in Nashville for production of single-use technologies products
Investment will further expand CDMO’s global network of SUT facilities to boost reliable supply of critical materials used to produce new biologics and vaccines
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance